Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Bicycle Therapeutics ( (BCYC) ) has issued an update.
On May 21, 2026, Bicycle Therapeutics reported initial data from its Duravelo-2 randomized Phase 2 trial of zelenectide pevedotin in previously untreated metastatic urothelial cancer, showing response rates comparable to standard of care and a potentially improved safety profile, both as monotherapy and in combination with pembrolizumab. Interim analyses from 2025 in Duravelo-2 and updated August 1, 2025 Duravelo-1 Phase 1 results indicated durable responses, encouraging progression-free survival and lower rates of neuropathy and skin toxicity, reinforcing the potential of the company’s Bicycle technology and setting up more detailed Phase 2 data in the second half of 2026.
In Duravelo-2’s combination cohort, an optimal zelenectide dose achieved an overall response rate above 60%, high treatment retention and limited dose-limiting adverse events, while monotherapy in pretreated patients delivered meaningful responses with manageable safety. Duravelo-1 data in cisplatin-ineligible and EV-naïve patients further demonstrated clinically relevant response rates and disease control with no new safety signals, positioning zelenectide as a differentiated Nectin-4–targeting therapy that could challenge current metastatic urothelial cancer standards if later-stage trials confirm these findings.
The most recent analyst rating on (BCYC) stock is a Hold with a $4.45 price target. To see the full list of analyst forecasts on Bicycle Therapeutics stock, see the BCYC Stock Forecast page.
Spark’s Take on BCYC Stock
According to Spark, TipRanks’ AI Analyst, BCYC is a Neutral.
The score is held down primarily by large ongoing losses and substantial cash burn, despite a low-debt balance sheet. Technicals also remain weak with the stock trading below key moving averages and negative MACD. Offsetting factors include a positive, notable pipeline update, but valuation support is limited given ongoing losses and no stated dividend yield.
To see Spark’s full report on BCYC stock, click here.
More about Bicycle Therapeutics
Bicycle Therapeutics plc is a clinical-stage pharmaceutical company listed on Nasdaq that is developing a novel class of medicines based on its proprietary bicyclic peptide technology. The company focuses on Bicycle Drug Conjugates targeting validated tumor antigens to deliver oncology therapeutics that aim to improve efficacy and tolerability over existing antibody-based modalities.
Average Trading Volume: 455,107
Technical Sentiment Signal: Sell
Current Market Cap: $308.1M
For a thorough assessment of BCYC stock, go to TipRanks’ Stock Analysis page.